DigestRedComo funciona
Red
/
Empresas
A2
No verificado

A2 Biotherapeutics, Inc.

Sobre qué escribimos

BiotecnologíaFarmacéuticaMedicina - VariosOncologíaSalud

12 Comunicados de prensa

Ver todos los comunicados de prensa
15/09/2026
Ciencia
Biotecnología
Farmacéutica
Oncología
Salud
Medicina - Varios
Eventos
Industria
A2 Biotherapeutics Presents Early Safety and Efficacy Data from the DENALI-1 Study of A2B395, Highlighting First Reported Case of Complete Response to CAR T-Cell Therapy in Anal Cancer and Partial Response at 6 Months in Refractory Head & Neck Cancer
Fuente
A2 Biotherapeutics, Inc.
Editor
Business Wire
1.00
0
21/05/2026
Ciencia
Biotecnología
Farmacéutica
Oncología
Salud
Medicina - Varios
Eventos
Industria
A2 Biotherapeutics Presents Safety and Efficacy Data from the EVEREST-2 Clinical Study, Including Update on the First Complete Response to CAR T-Cell Therapy in a Patient with Non-Small Cell Lung Cancer
Fuente
A2 Biotherapeutics, Inc.
Editor
Business Wire
1.00
0
22/04/2026
Eventos
Industria
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Oncología
A2 Biotherapeutics to Highlight Progress of CAR T-Cell Clinical Programs in Three Poster Presentations During the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
Fuente
A2 Biotherapeutics, Inc.
Editor
Business Wire
1.00
0
01/04/2026
Industria
Biotecnología
Higiene alimentaria
Salud
Farmacéutica
Oncología
A2 Biotherapeutics Receives U.S. FDA Fast Track Designation for A2B543, a Logic-Gated CAR T-Cell Therapy Enhanced with a Membrane-Tethered IL-12 Booster
Fuente
A2 Biotherapeutics, Inc.
Editor
Business Wire
1.00
0
26/02/2026
Industria
Ciencia
Biotecnología
Farmacéutica
Oncología
Salud
Medicina - Varios
A2 Biotherapeutics Doses First Patient in EVEREST-2 Study with A2B543, a Logic-Gated CAR T Cell Therapy Enhanced with a Membrane-Tethered IL-12 Booster
Fuente
A2 Biotherapeutics, Inc.
Editor
Business Wire
1.00
0
08/01/2026
Industria
Ciencia
Higiene alimentaria
Biotecnología
Medicina - Varios
Sanidad
Farmacéutica
Salud
Oncología
A2 Biotherapeutics Announces FDA Clearance of IND for A2B543 for Treatment of Adults with Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors that Express Mesothelin and Have Lost HLA-A*02 Expression
Fuente
A2 Biotherapeutics, Inc.
Editor
Business Wire
1.00
0
03/10/2025
Ciencia
Biotecnología
Farmacéutica
Oncología
Sanidad
Salud
Medicina - Varios
Eventos
Industria
A2 Bio to Present Early Safety and Efficacy Data from EVEREST-2 Study during 2025 Annual Meeting of the Society for Immunotherapy of Cancer
Fuente
A2 Biotherapeutics, Inc.
Editor
Business Wire
1.00
0
08/09/2025
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Oncología
Eventos
Industria
A2 Biotherapeutics Presents Data from Ongoing Phase 1/2 EVEREST-2 Study During the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer
Fuente
A2 Biotherapeutics, Inc.
Editor
Business Wire
1.00
0
26/06/2025
Oncología
Salud
Biología
Biotecnología
Medicina - Varios
Farmacéutica
Industria
A2 Bio Announces First Patient Dosed in DENALI-1 Phase 1/2 Clinical Study of A2B395, a Novel Allogeneic Precision CAR T Cell Therapy for Patients with Solid Tumors that Express EGFR
Fuente
A2 Biotherapeutics, Inc.
Editor
Business Wire
1.00
0
09/01/2025
Industria
Oncología
Salud
Biotecnología
Medicina - Varios
Farmacéutica
A2 Biotherapeutics Closes $80 Million Series C Financing to Advance Clinical Development of Its Precision Cell Therapies Using Its Proprietary Tmod™ Technology Platform
Fuente
A2 Biotherapeutics, Inc.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0